A
Adrian P. Gee
Researcher at Center for Cell and Gene Therapy
Publications - 306
Citations - 24049
Adrian P. Gee is an academic researcher from Center for Cell and Gene Therapy. The author has contributed to research in topics: Antigen & Transplantation. The author has an hindex of 67, co-authored 303 publications receiving 21132 citations. Previous affiliations of Adrian P. Gee include University of Toronto & Baxter International.
Papers
More filters
Journal ArticleDOI
Inducible apoptosis as a safety switch for adoptive cell therapy
Antonio Di Stasi,Siok-Keen Tey,Gianpietro Dotti,Yuriko Fujita,Alana A. Kennedy-Nasser,Caridad Martinez,Karin Straathof,Enli Liu,April G. Durett,Bambi Grilley,Hao Liu,Conrad Russell Y. Cruz,Barbara Savoldo,Adrian P. Gee,John Schindler,Robert A. Krance,Helen E. Heslop,David M. Spencer,Cliona M. Rooney,Malcolm K. Brenner +19 more
TL;DR: The inducible T-cell safety switch based on the fusion of human caspase 9 to a modified human FK-binding protein, allowing conditional dimerization may increase the safety of cellular therapies and expand their clinical applications.
Journal ArticleDOI
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Martin Pule,Barbara Savoldo,G. Doug Myers,G. Doug Myers,Claudia Rossig,Heidi V. Russell,Heidi V. Russell,Gianpietro Dotti,Gianpietro Dotti,M. Helen Huls,Enli Liu,Adrian P. Gee,Adrian P. Gee,Zhuyong Mei,Eric Yvon,Heidi L. Weiss,Hao Liu,Cliona M. Rooney,Cliona M. Rooney,Helen E. Heslop,Helen E. Heslop,Malcolm K. Brenner,Malcolm K. Brenner +22 more
TL;DR: It is shown in individuals with neuroblastoma that EBV-specific CTLs expressing a chimeric GD2-specific receptor indeed survive longer than T cells activated by the CD3-specific antibody OKT3 and expressing the same chimeric receptor but lacking virus specificity.
Journal ArticleDOI
Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma
Chrystal U. Louis,Chrystal U. Louis,Barbara Savoldo,Barbara Savoldo,Gianpietro Dotti,Gianpietro Dotti,Martin Pule,Eric Yvon,G. Doug Myers,Claudia Rossig,Heidi V. Russell,Oumar Diouf,Oumar Diouf,Enli Liu,Hao Liu,Meng Fen Wu,Adrian P. Gee,Zhuyong Mei,Cliona M. Rooney,Cliona M. Rooney,Helen E. Heslop,Helen E. Heslop,Malcolm K. Brenner,Malcolm K. Brenner +23 more
TL;DR: It is shown that GD2-CAR T cells can induce complete tumor responses in patients with active neuroblastoma; these CAR T cells may have extended, low-level persistence in patients, and such persistence was associated with longer survival.
Journal ArticleDOI
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
Issa F. Khouri,Michael J. Keating,M. Korbling,Donna Przepiorka,Paolo Anderlini,Susan O'Brien,Sergio Giralt,Cindy Ippoliti,B. Von Wolff,James Gajewski,M. Donato,David F. Claxton,Naoto T. Ueno,Borje S. Andersson,Adrian P. Gee,Richard E. Champlin +15 more
TL;DR: The ability to induce remissions with donor lymphocyte infusion in patients with CLL, Richter's, and low-grade and intermediate-grade lymphoma is direct evidence of GVL activity against lymphoid malignancies.
Journal ArticleDOI
CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
Barbara Savoldo,Carlos A. Ramos,Carlos A. Ramos,Enli Liu,Martha P. Mims,Michael J. Keating,George Carrum,George Carrum,Rammurti T. Kamble,Rammurti T. Kamble,Catherine M. Bollard,Catherine M. Bollard,Adrian P. Gee,Zhuyong Mei,Hao Liu,Bambi Grilley,Bambi Grilley,Cliona M. Rooney,Cliona M. Rooney,Helen E. Heslop,Malcolm K. Brenner,Gianpietro Dotti +21 more
TL;DR: The results demonstrate the superiority of CARs with dual signal domains and confirm a method of comparing CAR-modified T cells within individual patients, thereby avoiding patient-to-patient variability and accelerating the development of optimal T cell immunotherapies.